ArticleCancers2026
Treatment Allocation and Survival Outcomes in Potentially Resectable Colorectal Liver Metastases: A Real-World Cohort Study from Thailand.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesLiver resection is a potentially curative treatment for colorectal liver metastases (CRLM), but some potentially resectable patients may not reach specialist hepatobiliary assessment. This study evaluated treatment allocation, survival outcomes, and the potential gap between resectability and actual liver resection in a real-world Thai cohort.
methodsWe retrospectively reviewed 265 patients with CRLM treated at a tertiary-care hospital in Thailand between 2012 and 2022. Patients were classified into liver resection (LR;
resultsMedian OS was 59 months in the LR group and 23 months in the NLR group. In the NLR group, age < 65 years (adjusted HR 0.663, 95% CI 0.458-0.960;
conclusionsA clinically relevant subgroup of non-resected patients met predefined criteria for potential resectability on retrospective specialist reassessment. These findings should be interpreted as real-world treatment-allocation observations rather than evidence of a causal survival benefit of LR and support early hepatobiliary referral and repeated multidisciplinary assessment of resectability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.